Drew A. Torigian

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Gregory L. Beatty, E. Gabriela Chiorean, Matthew P. Fishman et al. · Science · 2011 · 1.6K citations

Medicine, Immunology, Oncology +17

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus et al. · Cancer Immunology Research · 2013 · 860 citations · Full text

Life Sciences, Immunology, Oncology +17

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Gregory L. Beatty, Mark H. O’Hara, Simon F. Lacey et al. · Gastroenterology · 2018 · 500 citations · Full text

Medicine, Immunology, Oncology +12

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Gregory L. Beatty, Drew A. Torigian, E. Gabriela Chiorean et al. · Clinical Cancer Research · 2013 · 452 citations · Full text

Medicine, Oncology, Pharmacology +16

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

János L. Tanyi, Sara Bobisse, Eran Ophir et al. · Science Translational Medicine · 2018 · 441 citations

Medicine, Immunology, Oncology +17